Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

Mirvetuximab soravtansine (MIRV) is a first-in-class antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) and is indicated for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrew Hendershot (Author), Mark Slabaugh (Author), Kamran M. Riaz (Author), Kathleen N. Moore (Author), David M. O'Malley (Author), Ursula Matulonis (Author), Gottfried E. Konecny (Author)
Format: Book
Published: Elsevier, 2023-06-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items